BiologicalDrug
Depemokimab clinical trials
Also written GSK3511294.
- studies test it
- 19
- open now
- 8
- in phase 3
- 14
- first study started
- 2017
Keep track of what changes. Save the depemokimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
19 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 4 |
| 2022 | 6 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 3
- 14
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 10
Who runs them
Industry 18 · Other 1
Studies
Open first, then newest update. How each study uses depemokimab is read from its arms, and is right about nine times in ten.
Testing it · 19
- Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)RecruitingPhase 3GlaxoSmithKlineNCT06961214Written as Depemokimab
- Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationRecruitingPhase 3GlaxoSmithKlineNCT06959095Written as Depemokimab
- Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic AsthmaNot yet recruitingNot applicableQianfoshan HospitalNCT07828327Written as Depemokimab
- Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)RecruitingPhase 4GlaxoSmithKlineNCT07701967Written as Depemokimab
- A Study of Depemokimab in Participants of 6 to 11 Years of AgeRecruitingPhase 3GlaxoSmithKlineNCT07671001Written as Depemokimab
- A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 AsthmaRecruitingPhase 3GlaxoSmithKlineNCT07456033Written as Depemokimab
- eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationRecruitingPhase 3GlaxoSmithKlineNCT07177339Written as Depemokimab
- Depemokimab Asthma Imaging and Bronchoscopy Sub-StudyRecruitingPhase 3GlaxoSmithKlineNCT06979323Written as Depemokimab
- Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialActive, not recruitingPhase 3GlaxoSmithKlineNCT05334368Written as Depemokimab
- Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)Active, not recruitingPhase 3GlaxoSmithKlineNCT05263934Written as Depemokimab
- A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult ParticipantsCompletedPhase 1GlaxoSmithKlineNCT05602025Written as Depemokimab
- Study of GSK3511294 in Healthy Chinese ParticipantsCompletedPhase 1GlaxoSmithKlineNCT05140200Written as Depemokimab
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypeCompletedPhase 3GlaxoSmithKlineNCT04718389Written as GSK3511294 (Depemokimab)
- An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)CompletedPhase 3GlaxoSmithKlineNCT05243680Written as GSK3511294 (Depemokimab)
- Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal PolypsCompletedPhase 3GlaxoSmithKlineNCT05274750Written as Depemokimab (GSK3511294)
- Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)CompletedPhase 3GlaxoSmithKlineNCT05281523Written as Depemokimab (GSK3511294)
- Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic PhenotypeCompletedPhase 3GlaxoSmithKlineNCT04719832Written as GSK3511294 (Depemokimab)
- A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic PhenotypeCompletedPhase 3GlaxoSmithKlineNCT04718103Written as GSK3511294
- First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate AsthmaCompletedPhase 1GlaxoSmithKlineNCT03287310Written as GSK3511294
Codes
What other systems call depemokimab · ClinicalTrials.gg INT002183
- MeSH (NLM) C000731964depemokimabOne source NLM
- UNII (FDA) D16EQP0KKHDEPEMOKIMABConfirmed FDA, NLM
- NCI Thesaurus C175768DepemokimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731964 | depemokimab | One source NLM |
| UNII (FDA) | D16EQP0KKH | DEPEMOKIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C175768 | Depemokimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.